@article{e5f129bea95c4b6baad95341a3e224f9,
title = "Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes",
keywords = "apolipoprotein, cardiovascular diseases, chylomicrons, evolocumab, kinetics, TRIGLYCERIDE-RICH LIPOPROTEINS, PCSK9 INHIBITOR EVOLOCUMAB, SUBTILISIN/KEXIN TYPE 9, CARDIOVASCULAR-DISEASE, 000 PARTICIPANTS, LDL CHOLESTEROL, REDUCING LIPIDS, EFFICACY, SAFETY, METABOLISM, 3121 General medicine, internal medicine and other clinical medicine",
author = "MR Taskinen and E Bjornson and J Kahri and S Soderlund and N Matikainen and K Porthan and M Ainola and A Hakkarainen and N Lundbom and V Fermanelli and J Fuchs and A Thorsell and F Kronenberg and L Andersson and M Adiels and CJ Packard and J Boren",
year = "2021",
month = feb,
doi = "10.1161/ATVBAHA.120.315446",
language = "English",
volume = "41",
pages = "962--975",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott williams & wilkins",
number = "2",
}